Autonomic Nervous System Drugs Practice Questions

Q: A 45-year-old patient has recently received a heart transplant. Patient education has included descriptions of the potential cardiovascular effects of pharmacologic agents. Which one of the following drugs is least likely to cause tachycardia?

Amphetamine. **Explanation:**The core concept in this question is the physiological state of a **denervated heart** following a transplant. In a heart transplant recipient, the autonomic nerve supply (both sympathetic and parasympathetic) is severed. Consequently, the heart can only respond to drugs that act **directly** on cardiac receptors [1].**1. Why Amphetamine is the correct answer:**Amphetamine is an **indirect-acting sympathomimetic**. It works by displacing stored norepinephrine from the presynaptic nerve terminals. In a transplanted heart, these sympathetic nerve endings have degenerated (denervation). Therefore, there is no norepinephrine available for amphetamine to release, and it fails to produce its characteristic tachycardic effect [2].**2. Why the other options are incorrect:** * **Dobutamine, Epinephrine, and Isoproterenol** are all **direct-acting agonists**. They act directly on the $\beta_1$-adrenergic receptors located on the myocardium and the SA node. Since the receptors themselves remain functional after transplantation, these drugs will still cause tachycardia. In fact, due to "denervation supersensitivity," the heart may show an exaggerated response to direct-acting agents like Isoproterenol [1].**NEET-PG High-Yield Pearls:** * **Denervated Heart:** The resting heart rate is typically higher (90–100 bpm) because the inhibitory influence of the Vagus nerve is lost [1]. * **Atropine:** This drug will **not** work to treat bradycardia in a transplant patient because its mechanism (blocking vagal tone) requires intact innervation. * **Reflexes:** Baroreceptor reflex-mediated changes in heart rate (e.g., reflex tachycardia from Nitroglycerin) are absent in these patients. * **Direct vs. Indirect:** Always distinguish between these two for "denervation" questions.

Q: Propranolol can be used in all of the following conditions EXCEPT:

Variant angina. **Explanation:** **Variant Angina (Prinzmetal Angina)** is the correct answer because Propranolol, a non-selective beta-blocker, is **contraindicated** in this condition. Variant angina is caused by coronary artery vasospasm rather than atherosclerosis. By blocking $eta_2$ receptors (which mediate vasodilation), Propranolol leaves $\alpha_1$ receptors unopposed. This leads to exaggerated vasoconstriction, potentially worsening the spasm and causing myocardial ischemia [5]. **Why other options are incorrect:** * **Thyrotoxicosis:** Propranolol is the drug of choice to control symptomatic tachycardia and tremors. It also uniquely inhibits the peripheral conversion of $T_4$ to the more active $T_3$ [1]. * **Migraine:** Propranolol is a first-line agent for the **prophylaxis** of migraine (not acute attacks) due to its lipophilic nature and ability to cross the blood-brain barrier [1]. * **Hypertension:** While no longer first-line for uncomplicated hypertension, beta-blockers remain effective, especially in patients with co-existing conditions like stable angina or post-myocardial infarction [2]. **High-Yield Clinical Pearls for NEET-PG:** 1. **Drug of Choice for Variant Angina:** Calcium Channel Blockers (CCBs) like Diltiazem or Nitrates. 2. **Lipophilicity:** Propranolol is highly lipid-soluble, explaining its CNS side effects (vivid dreams/nightmares) and its efficacy in migraine and essential tremors [3]. 3. **Contraindications:** Avoid Propranolol in **Asthma/COPD** (due to $eta_2$ blockade causing bronchospasm), **Decompensated Heart Failure**, and **Diabetes Mellitus** (masks hypoglycemic tachycardia) [4].

Q: A patient received a placebo therapy, and another patient received a new drug. Given the following comparative data, what classes of drugs were likely administered? Placebo: Heart rate 72, SBP 110, DBP 80, Cardiac output 5. New Drug: Heart rate 86, SBP 150, DBP 68, Cardiac output 6.

Alpha-1 antagonist and Beta agonist. ### Explanation To identify the drug class, we must analyze the hemodynamic changes compared to the placebo baseline: 1. **Heart Rate (72 → 86):** An increase (tachycardia) suggests **Beta-1 stimulation** or a reflex response. 2. **Systolic BP (110 → 150):** A significant increase indicates increased **Cardiac Output (CO)** and/or stroke volume, primarily mediated by **Beta-1 receptors**. 3. **Diastolic BP (80 → 68):** A decrease indicates a reduction in **Total Peripheral Resistance (TPR)**. This occurs via **Alpha-1 blockade** or **Beta-2 stimulation** (vasodilation). 4. **Cardiac Output (5 → 6):** An increase confirms positive inotropic and chronotropic effects (**Beta-1 effect**). **Why Option A is Correct:** A **Beta agonist** (like Isoprenaline or Dobutamine) explains the increased HR, SBP, and CO. An **Alpha-1 antagonist** (like Phentolamine) explains the drop in DBP by preventing vasoconstriction, leading to decreased peripheral resistance. **Analysis of Incorrect Options:** * **B & C (Alpha-1 agonist):** Alpha-1 agonists cause potent vasoconstriction, which would **increase** DBP significantly and often cause reflex bradycardia. * **D (Beta agonist + Beta-2 agonist):** While this would increase CO and decrease DBP, the combination lacks the specific Alpha-antagonism often tested in "mixed effect" scenarios. However, the primary differentiator in NEET-PG patterns is that Alpha-1 agonists are excluded due to the *drop* in DBP. **NEET-PG High-Yield Pearls:** * **SBP** is primarily determined by **Cardiac Output** (Beta-1). * **DBP** is primarily determined by **Peripheral Resistance** (Alpha-1 and Beta-2). * **Pulse Pressure (SBP - DBP):** Widens significantly with Beta-1 stimulation combined with Alpha-1 blockade or Beta-2 stimulation. * **Isoprenaline** (Non-selective Beta agonist) typically increases SBP, increases HR, and decreases DBP—mimicking the "New Drug" profile in this question.

Q: In recommending treatment for a patient with carcinoid syndrome, which of the following medications would NOT be considered?

Sumatriptan. **Explanation** **Carcinoid syndrome** is characterized by the excessive secretion of serotonin (5-HT) from neuroendocrine tumors [4]. Management focuses on blocking serotonin receptors or inhibiting its release. **Why Sumatriptan is the Correct Answer:** Sumatriptan is a **5-HT$_{1B/1D}$ receptor agonist** used primarily for the acute treatment of migraines [2],[3]. In carcinoid syndrome, the goal is to **antagonize** the effects of excess serotonin. Administering a serotonin agonist like Sumatriptan would be counter-productive and is not indicated in the management of this syndrome. **Analysis of Incorrect Options:** * **Cyproheptadine:** A potent **5-HT$_2$ receptor antagonist** (also has H$_1$ blocking properties). It is frequently used to control the diarrhea and flushing associated with carcinoid syndrome. * **Ketanserin:** A selective **5-HT$_{2A}$ antagonist** that also blocks $\alpha_1$-adrenoceptors. It is effective in managing the vasomotor symptoms (flushing) and hypertension in these patients. * **Methysergide:** An ergot derivative that acts as a **5-HT$_{2A/2C}$ antagonist**. While effective for carcinoid symptoms, its long-term use is limited by the risk of retroperitoneal and subendocardial fibrosis [1]. **High-Yield Clinical Pearls for NEET-PG:** * **Drug of Choice (DOC):** **Octreotide** (a long-acting Somatostatin analogue) is the gold standard for controlling symptoms and reducing 5-HIAA levels in carcinoid syndrome. * **Diagnostic Marker:** 24-hour urinary **5-HIAA** (5-Hydroxyindoleacetic acid) is the primary metabolite used for diagnosis. * **Pellagra Risk:** Patients may develop Niacin (Vitamin B3) deficiency because dietary Tryptophan is diverted toward massive Serotonin production rather than Niacin synthesis.

Q: Botulinum toxin is used in the treatment of which of the following conditions?

Both Achalasia cardia and Torticollis. ### Explanation **Mechanism of Action:** Botulinum toxin (produced by *Clostridium botulinum*) acts by irreversibly inhibiting the release of **Acetylcholine (ACh)** from the presynaptic nerve terminals at the neuromuscular junction [1]. It does this by cleaving **SNARE proteins** (specifically SNAP-25), preventing the fusion of synaptic vesicles with the plasma membrane. This results in flaccid paralysis of the targeted muscle [1]. **Why Option C is Correct:** Botulinum toxin is clinically utilized in conditions characterized by muscle overactivity or spasms: 1. **Achalasia Cardia:** It is injected into the **Lower Esophageal Sphincter (LES)** to induce relaxation, thereby relieving the functional obstruction caused by the failure of the LES to relax. 2. **Torticollis (Cervical Dystonia):** Local injections into the overactive neck muscles (like the sternocleidomastoid) help reduce painful contractions and abnormal head positioning. **Analysis of Other Options:** * **Option A & B:** While both are correct indications, selecting either individually would be incomplete as the toxin is an established treatment modality for both conditions. **NEET-PG High-Yield Pearls:** * **Other Clinical Uses:** Strabismus (first FDA-approved use), Blepharospasm, Hemifacial spasm, Chronic Migraine, Hyperhidrosis (excessive sweating), and Cosmetic "Botox" for wrinkles. * **Types:** Type A (Botox) is the most commonly used clinical form. * **Antidote:** In cases of botulism poisoning, equine antitoxin is used, but it cannot reverse existing paralysis; it only prevents further toxin binding [1]. * **Key Anatomical Target:** The **SNARE complex** (Synaptosomal-Associated Protein).

Q: Which beta-blocker possesses intrinsic sympathomimetic activity?

Celiprolol. ### Explanation **Correct Answer: D. Celiprolol** **Understanding the Concept: Intrinsic Sympathomimetic Activity (ISA)** Beta-blockers with ISA are **partial agonists**. While they bind to beta-receptors and block the effects of endogenous catecholamines (like epinephrine), they also cause low-level activation of the receptor. This results in less resting bradycardia and less peripheral vasoconstriction compared to pure antagonists. **Celiprolol** is a unique third-generation cardioselective ($\beta_1$) blocker that also possesses **$\beta_2$ agonist activity** (ISA) and weak $\alpha_2$ blocking properties. This makes it particularly useful in patients with reactive airway disease or peripheral vascular disease where pure beta-blockade might be contraindicated. **Analysis of Incorrect Options:** * **A. Propranolol:** A prototype non-selective beta-blocker ($\beta_1 + \beta_2$). It is a **pure antagonist** and lacks ISA. It is highly lipid-soluble and frequently used for migraine prophylaxis and portal hypertension. * **B. Atenolol:** A second-generation **cardioselective ($\beta_1$) blocker**. It is hydrophilic, has no ISA, and is primarily excreted by the kidneys. * **C. Bisoprolol:** A highly **$\beta_1$-selective blocker** without ISA. It is a mainstay in the management of chronic heart failure (along with Carvedilol and Metoprolol succinate). **High-Yield Clinical Pearls for NEET-PG:** * **Mnemonic for ISA:** "**P**in **P**ale **C**ats" → **P**indolol (strongest ISA), **P**enbutolol, **C**eliprolol, **A**cebutolol, **L**abetalol, **E**panolol. * **Clinical Advantage:** Beta-blockers with ISA are preferred in patients prone to **bradycardia**, as they maintain a higher resting heart rate. * **Celiprolol Speciality:** It is often highlighted in exams for its "vasodilatory" beta-blocker status due to its $\beta_2$ agonism.

Q: Propranolol is useful in all conditions listed, except:

Parkinsonian tremor. **Explanation:** The correct answer is **Parkinsonian tremor** because Propranolol, a non-selective beta-blocker, has no therapeutic role in treating the tremors associated with Parkinson’s disease. Parkinsonian tremors are "resting tremors" caused by a dopamine-acetylcholine imbalance in the basal ganglia. In contrast, Propranolol is the drug of choice for **Essential tremors** (action tremors), which are mediated by peripheral $\beta_2$ receptors. **Analysis of Options:** * **Migraine (A):** Propranolol is a first-line agent for the **prophylaxis** of migraine. It works by preventing vasodilation and modulating cortical excitability, though it is not used for acute attacks. * **Thyrotoxicosis (B):** It is used to control symptoms like tachycardia, palpitations, and tremors. Additionally, it inhibits the peripheral conversion of $T_4$ to the more active $T_3$. * **Esophageal Varices (D):** Propranolol is used for primary and secondary prophylaxis of variceal bleeding. It reduces portal pressure by causing splanchnic vasoconstriction (via $\beta_2$ blockade) and reducing cardiac output (via $\beta_1$ blockade). **NEET-PG High-Yield Pearls:** * **Drug of Choice (DOC):** Propranolol is the DOC for **Essential Tremor**, **Performance Anxiety** (Stage fright), and **Infantile Hemangioma**. * **Contraindications:** Avoid in Bronchial Asthma (causes bronchospasm), Insulin-dependent Diabetes (masks hypoglycemic tachycardia), and Prinzmetal Angina. * **Membrane Stabilizing Activity (MSA):** Propranolol possesses significant local anesthetic activity, making it unsuitable for topical ophthalmic use (risk of corneal anesthesia).

Q: All of the following are cardioselective beta blockers EXCEPT?

Propranolol. **Explanation:** The question tests the classification of beta-blockers based on their receptor selectivity. Beta-blockers are divided into non-selective (Generation I) and cardioselective (Generation II). **1. Why Propranolol is the correct answer:** **Propranolol** is a **non-selective (1st generation) beta-blocker**. It blocks both $\beta_1$ receptors (located primarily in the heart) and $\beta_2$ receptors (located in bronchial smooth muscle, blood vessels, and liver). Because it lacks selectivity, it is contraindicated in patients with bronchial asthma or COPD due to the risk of bronchospasm. **2. Why the other options are incorrect:** Options A, B, and C are all **Cardioselective ($\beta_1$ selective) blockers**. They primarily inhibit $\beta_1$ receptors at standard doses, making them safer for patients with respiratory issues or diabetes. * **Atenolol:** A long-acting, hydrophilic $\beta_1$ blocker commonly used for hypertension. * **Esmolol:** An ultra-short-acting $\beta_1$ blocker (half-life ~9 minutes) administered IV, used for acute arrhythmias or intraoperative tachycardia. * **Bisoprolol:** A highly selective $\beta_1$ blocker often preferred in the management of chronic heart failure. **3. High-Yield Clinical Pearls for NEET-PG:** * **Mnemonic for Cardioselective ($\beta_1$) blockers:** *"**A**ll **N**ew **B**eta **B**lockers **E**xert **M**ainly **C**ardioselective **A**ctions"* (**A**tenolol, **N**ebivolol, **B**isoprolol, **B**etaxolol, **E**smolol, **M**etoprolol, **C**eliprolol, **A**cebutolol). * **Nebivolol** is the most highly selective $\beta_1$ blocker and also possesses vasodilatory properties via Nitric Oxide (NO) release. * **Propranolol** is highly lipid-soluble, crosses the blood-brain barrier, and is the drug of choice for **prophylaxis of migraine** and **essential tremors**.

Question 1

A 45-year-old patient has recently received a heart transplant. Patient education has included descriptions of the potential cardiovascular effects of pharmacologic agents. Which one of the following drugs is least likely to cause tachycardia?

Accepted Answer

Amphetamine

Answer

Dobutamine

Answer

Epinephrine

Answer

Isoproterenol

Question 2

Propranolol can be used in all of the following conditions EXCEPT:

Accepted Answer

Variant angina

Answer

Thyrotoxicosis

Answer

Migraine

Answer

Hypertension

Question 3

A patient received a placebo therapy, and another patient received a new drug. Given the following comparative data, what classes of drugs were likely administered? Placebo: Heart rate 72, SBP 110, DBP 80, Cardiac output 5. New Drug: Heart rate 86, SBP 150, DBP 68, Cardiac output 6.

Accepted Answer

Alpha-1 antagonist and Beta agonist

Answer

Alpha-1 agonist and M3 agonist

Answer

Alpha-1 agonist and Beta agonist

Answer

Beta agonist and Beta-2 agonist

Question 4

In recommending treatment for a patient with carcinoid syndrome, which of the following medications would NOT be considered?

Accepted Answer

Sumatriptan

Answer

Cyproheptadine

Answer

Ketanserin

Answer

Methysergide

Question 5

Atropine when used as a pre-medication causes all of the following symptoms except:

Accepted Answer

Bronchoconstriction

Answer

Skin flush

Answer

Prevents bradycardia

Answer

Dryness of mouth

Question 6

Botulinum toxin is used in the treatment of which of the following conditions?

Accepted Answer

Both Achalasia cardia and Torticollis

Answer

Achalasia cardia

Answer

Torticollis

Answer

None of the above

Question 7

Which beta-blocker possesses intrinsic sympathomimetic activity?

Accepted Answer

Celiprolol

Answer

Propranolol

Answer

Atenolol

Answer

Bisoprolol

Question 8

Propranolol is useful in all conditions listed, except:

Accepted Answer

Parkinsonian tremor

Answer

Migraine

Answer

Thyrotoxicosis

Answer

Esophageal varices

Question 9

All of the following are cardioselective beta blockers EXCEPT?

Accepted Answer

Propranolol

Answer

Atenolol

Answer

Esmolol

Answer

Bisoprolol

Question 10

Which one of the following statements is true about dipivefrine?

Accepted Answer

It penetrates the cornea and is converted to epinephrine.

Answer

It is a prodrug.

Answer

It causes vasoconstriction.

Answer

It decreases intraocular pressure.

Autonomic Nervous System Drugs — MCQs

Autonomic Nervous System Drugs — MCQs

On this page

Practice by Chapter

Want unlimited practice?